A Phase 1 interventional study of Enlicitide Chloride and Placebo in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in China. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-07.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to learn about the safety of enlicitide chloride and how well people tolerate it. Researchers also want to learn what happens to different amounts of enlicitide chloride in a healthy person's body over time.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion criteria include, but are not limited to:
Exclusion Criteria:
Exclusion criteria include, but are not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: Participants will receive a single dose of enlicitide chloride dose 1 or a single dose of placebo on Day 1 on an empty stomach (after a ≥8-hour overnight fast). Period 2: Participants will receive a single dose of enlicitide chloride dose 1 or a single dose of placebo on Day 1 on an empty stomach (after a ≥8-hour overnight fast) followed by a standard breakfast.
Drug: Enlicitide Chloride · Drug: Placebo
Period 1: Participants will receive a single dose of enlicitide chloride dose 2 or a single dose of placebo on Day 1 on an empty stomach (after a ≥8-hour overnight fast). Period 2: Participants will receive a single dose of enlicitide chloride dose 3 or a single dose of placebo on Day 1 on an empty stomach (after a ≥8-hour overnight fast).
Drug: Enlicitide Chloride · Drug: Placebo
Participants will receive enlicitide chloride dose 2 or placebo once daily for 14 days on an empty stomach (after a ≥8-hour overnight fast).
Drug: Enlicitide Chloride · Drug: Placebo
Oral Capsule
Also known as: MK-0616
Placebo oral capsule matching enlicitide chloride
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention
Time frame: Up to approximately 2 months
Number of Participants Who Discontinue the Study Treatment Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention
Time frame: Up to approximately 2 months
Panels A and B: Area Under the Concentration-Time Curve from 0 to Infinity (AUC0-inf) of Enlicitide Chloride
Blood samples will be collected to determine the AUC0-inf of enlicitide chloride
Time frame: Predose and at designated timepoints (up to 8 days postdose)
Panels A and B: Area Under the Concentration-Time Curve from 0 to 24 Hours (AUC0-24) of Enlicitide Chloride
Blood samples will be collected to determine the AUC0-24 of enlicitide chloride
Time frame: Predose and at designated timepoints (up to 24 hours postdose)
Panels A and B: Area Under the Concentration-Time Curve from 0 to Last Measurable Concentration (AUC0-last) of Enlicitide Chloride
Blood samples will be collected to determine the AUC0-last of enlicitide chloride
Time frame: Predose and at designated timepoints (up to 8 days postdose)
Panels A and B: Maximum Plasma Concentration (Cmax) of Enlicitide Chloride
Blood samples will be collected to determine the Cmax of enlicitide chloride
Time frame: Predose and at designated timepoints (up to 8 days postdose)
Panels A and B: Time to Maximum Plasma Concentration (Tmax) of Enlicitide Chloride
Blood samples will be collected to determine the Tmax of enlicitide chloride
Time frame: Predose and at designated timepoints (up to 8 days postdose)
Panels A and B: Concentration at 24 Hours Postdose (C24) of Enlicitide Chloride
Blood samples will be collected to determine the C24 of enlicitide chloride
Time frame: 24 hours postdose
Panels A and B: Apparent Terminal Half-Life (t1/2) of Enlicitide Chloride
Blood samples will be collected to determine the apparent terminal t1/2 of enlicitide chloride
Time frame: Predose and at designated timepoints (up to 8 days postdose)
Panels A and B: Apparent Clearance (CL/F) of Enlicitide Chloride
Blood samples will be collected to determine the CL/F of enlicitide chloride
Time frame: Predose and at designated timepoints (up to 8 days postdose)
Panels A and B: Apparent Volume of Distribution During Terminal Phase (Vz/F) of Enlicitide Chloride
Blood samples will be collected to determine the Vz/F of enlicitide chloride
Time frame: Predose and at designated timepoints (up to 8 days postdose)
Panels A and B: Percent of Reduction of Serum Low Density Lipoprotein Cholesterol (LDL-C)
Blood samples will be collected to determine the percent of reduction of serum LDL-C
Time frame: Predose and at designated timepoints (up to 8 days postdose)
Panel C: AUC0-24 of Enlicitide Chloride
Blood samples will be collected to determine the AUC0-24 of enlicitide chloride
Time frame: Predose and at designated timepoints (up to 24 hours postdose)
Panel C: Cmax of Enlicitide Chloride
Blood samples will be collected to determine the Cmax of enlicitide chloride
Time frame: Predose and at designated timepoints (up to 14 days postdose)
Panel C: Tmax of Enlicitide Chloride
Blood samples will be collected to determine the Tmax of enlicitide chloride
Time frame: Predose and at designated timepoints (up to 14 days postdose)
Panel C: C24 of Enlicitide Chloride
Blood samples will be collected to determine the C24 of enlicitide chloride
Time frame: 24 hours postdose
Panel C: Apparent Terminal t1/2 of Enlicitide Chloride
Blood samples will be collected to determine the apparent terminal t/2 of enlicitide chloride
Time frame: Predose and at designated timepoints (up to 14 days postdose)
Panel C: CL/F of Enlicitide Chloride
Blood samples will be collected to determine the CL/F of enlicitide chloride
Time frame: Predose and at designated timepoints (up to 14 days postdose)
Panel C: Vz/F of Enlicitide Chloride
Blood samples will be collected to determine the Vz/F of enlicitide chloride
Time frame: Predose and at designated timepoints (up to 14 days postdose)
Panel C: Accumulation Ratio of Enlicitide Chloride
Blood samples will be collected to determine the accumulation ratio of enlicitide chloride
Time frame: Predose and at designated timepoints (up to 14 days postdose)
Panel C: Percent of Reduction of Serum LDL-C
Blood samples will be collected to determine the percent of reduction of serum LDL-C
Time frame: Predose and at designated timepoints (up to 14 days postdose)
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Mar 2023 to primary completion in May 2023, 2 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enlicitide chloride